Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | DHODH | Q02127 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.44 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4362422 | 0.83 | TP53 (0.50) | TP53HSD17B10KMT2AACHEPDE10A | |
| SCHEMBL619836 | 0.80 | DHODH (0.64) | ADORA2ATP53HSD17B10ACHEPDE10A | |
| SCHEMBL620119 | 0.79 | HSD17B10 (0.81) | TP53HSD17B10KMT2AACHEPDE10A | |
| SCHEMBL4360509 | 0.77 | ADORA2A (0.49) | ADORA2ATP53HSD17B10KMT2APDE10A | |
| SCHEMBL4363315 | 0.77 | HSD17B10 (0.46) | ADORA2ATP53HSD17B10KMT2AACHE | |
| SCHEMBL4553632 | 0.77 | TBK1 (0.41) | ADORA2AHSD17B10DHODHCSNK2A2CSNK2B | |
| SCHEMBL743112 | 0.76 | ALDH1A1 (0.48) | TP53HSD17B10KMT2APDE10ATSHR | |
| SCHEMBL10778674 | 0.74 | KMT2A (0.52) | ADORA2AKMT2APDE10ATSHRDHODH | |
| SCHEMBL8574197 | 0.73 | HSD17B10 (0.58) | TP53HSD17B10KMT2AACHEPDE10A | |
| SCHEMBL10000555 | 0.72 | KMT2A (0.45) | ADORA2AHSD17B10KMT2APDE10ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270450-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | US | disclosed |
| US-20090054411-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054411-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | CSF1R, CSF3R, FLT3 | ADORA2A 890/4885TP53 1588/4885HSD17B10 4775/4885 |
| US-20090270450-A1 | CHEMICAL COMPOUNDS | CSF1R, CSF3R, FLT3 | ADORA2A 1011/4885TP53 928/4885HSD17B10 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.